Riluzole
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||||||||
Non-proprietary name | Riluzole | |||||||||||||||||||||
other names |
6- (trifluoromethoxy) -1,3-benzothiazol-2-amine ( IUPAC ) |
|||||||||||||||||||||
Molecular formula | C 8 H 5 F 3 N 2 OS | |||||||||||||||||||||
Brief description |
white solid |
|||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 234.20 g · mol -1 | |||||||||||||||||||||
solubility |
> 25 g l −1 in DMSO |
|||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
Toxicological data | ||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Riluzole (trade name Rilutek ® ) is a drug that is used to treat amyotrophic lateral sclerosis (ALS). It extends the patient's survival time in this disease.
The chemical substance belongs to the group of benzothiazoles .
Use in psychiatry
Several recent case studies have shown that riluzole could be used successfully, especially in anxiety disorders.
A form of riluzole developed for sublingual use, known by the code name BHV-0223, is currently being developed by Biohaven Pharmaceuticals for the treatment of generalized anxiety and mood disorders.
Pharmacological properties
Riluzole is a sodium channel blocker and attenuates the effects of the neurotransmitter glutamate .
Individual evidence
- ↑ a b c d e Riluzole data sheet from Sigma-Aldrich , accessed on April 22, 2011 ( PDF ).
- ↑ Scientific discussion for the approval of RILUTEK ( en , PDF; 133 kB) European Medicines Agency . P. 12. January 1, 2004. Retrieved August 10, 2010.
- ↑ Paul Grant, Jane Y. Song, Susan E. Swedo: Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder . In: Journal of Child and Adolescent Psychopharmacology . tape 20 , no. 4 , August 2010, p. 309-315 , doi : 10.1089 / cap.2010.0009 , PMID 20807069 , PMC 2958461 (free full text).
- ↑ Riluzole sublingual - Biohaven Pharmaceutical - AdisInsight. Retrieved March 19, 2019 .
- ^ Elaine Harris: Industry update: the latest developments in therapeutic delivery . In: Therapeutic Delivery . 6, No. 6, 2015, pp. 647-652. doi : 10.4155 / tde.15.44 .